GI Cancer ASCO 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / gi-cancer-asco-2024-highlights

Following the 2024 ASCO Annual Meeting, Mark A. Lewis, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates in gastrointestinal cancer.

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

EP. 1: Recent Updates from the ESOPEC Trial in Esophageal Adenocarcinoma

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD
June 24th 2024

Following ASCO 2024, Mark A. Lewis, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on recent updates from the ESOPEC trial in esophageal adenocarcinoma.

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

EP. 2: Key Updates from ARMANI in Advanced HER2- Gastric/GEJ Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD
June 24th 2024

Mark A. Lewis, MD, and the Oncology Brothers discuss recent updates from the ARMANI trial in HER2- gastric/ gastroesophageal junction cancer.

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

EP. 3: TRANSMET: Chemotherapy Plus Liver Transplant in Unresectable Colorectal Liver Metastases

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD
June 24th 2024

Medical oncologists review recent data from the TRANSMET study evaluating chemotherapy plus liver transplantation in patients with unresectable colorectal liver metastases.

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

EP. 4: COLLISION: Surgery vs Thermal Ablation for Small-Size Colorectal Liver Mets

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD
June 24th 2024

The Oncology Brothers and Mark A. Lewis, MD, review recent updates from the COLLISION study that were presented at the 2024 ASCO Annual Meeting.

Mark A. Lewis, MD, with the Oncology Brothers presenting slides

EP. 5: Recent Data from COMMIT in dMMR/MSI-High Metastatic Colorectal Cancer

Rohit Gosain, MD;Rahul Gosain, MD;Mark A. Lewis, MD
June 24th 2024

Mark A. Lewis, MD, discusses recent data from the COMMIT trial investing first-line treatment of patients with deficient DNA mismatch repair or microsatellite instability–high metastatic colorectal cancer.